

Supporting Information

Facile Ru-catalysed synthesis of quinazolin-4(3H)-ones by tandem cyclization of 2-nitrobenzonitrile and alcohol derivatives under air

Ban Van Phuc,^a Tien Dat Nguyen,^b Nguyen T. Minh Tuan,^b Phuong Anh Dao,^b Phan T. Thao Vy,^b Hien Nguyen,^c Ngoc Tuan Nguyen,^a Quoc Anh Ngo,^{a,d} Tran Quang Hung,^{*a,d} Tuan Thanh Dang^{*b}

^a) Institute of Chemistry, Vietnam Academy of Science and Technology, Viet Nam.

^b) Faculty of Chemistry, Hanoi University of Science, Vietnam National University (VNU), Viet Nam.

^c) Faculty of Chemistry, Hanoi National University of Education (HNUE), Viet Nam.

^d) Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Viet Nam.


CONTENT

Experimental Section


Copies of NMR spectra

Experimental Section


General procedure for preparing of 2-phenylquinazolin-4(3*H*)-one **3a**¹




A pressure tube with a magnetic stirring bar was charged with 2-nitrobenzonitrile (50 mg, 0.338 mmol, 1 equiv.), benzyl alcohol (146 mg, 1.352 mmol, 4 equiv.), NaOH (27 mg, 0.675 mmol, 2 equiv.). Then, add the catalyst with $[\text{RuCl}_2(\text{COD})]_n$ (3.79 mg, 4 mol%). Toluene solvent (0.5 ml) was then introduced at the end. The reaction was carried out under air at a temperature of 90°C for 16 hours. After that, the reaction mixture was purified by column chromatography (eluent: hexane/ ethyl acetate (5/1)). Product **3a** was obtained as white solids, with yield of 92%. ¹H NMR (600 MHz, DMSO) δ 12.53 (s, 1H), 8.26 – 8.18 (m, 2H), 8.17 (dd, J = 7.9, 1.6 Hz, 1H), 7.88 – 7.82 (m, 1H), 7.76 (dd, J = 8.2, 1.1 Hz, 1H), 7.63 – 7.58 (m, 1H), 7.58 – 7.55 (m, 2H), 7.55 – 7.51 (m, 1H). ¹³C NMR (151 MHz, DMSO) δ 199.8, 190.0, 186.4, 172.2, 170.4, 169.0, 166.2, 165.4, 165.1, 164.2, 163.5, 158.6, 77.6, 77.4, 77.3, 77.2, 77.0, 76.9, 76.7.




2-(p-tolyl)quinazolin-4(3*H*)-one **3b¹** prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and p-tolylmethanol (122 mg, 1.352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3b** (89%) as a white solid. ¹H NMR (600 MHz, CDCl₃) δ 11.73 (s, 1H), 8.35 – 8.30 (m, 1H), 8.19 – 8.14 (m, 2H), 7.83 – 7.80 (m, 1H), 7.78 (ddd, J = 8.2, 6.8, 1.5 Hz, 1H), 7.48 (ddd, J = 8.1, 6.8, 1.5 Hz, 1H), 7.39 – 7.35 (m, 2H), 2.45 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 164.1, 152.0, 149.8, 142.3, 134.9, 130.2, 129.9, 128.1, 127.5, 126.6, 126.5, 120.9, 77.4, 77.1, 76.9, 21.6.




2-(m-tolyl)quinazolin-4(3H)-one 3c¹ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and m-tolylmethanol (122 mg, 1.352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3c** (90%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.5 (s, 1H), 8.2 (dd, J = 7.9, 1.5 Hz, 1H), 8.0 (tt, J = 1.8, 0.8 Hz, 1H), 8.0 – 8.0 (m, 1H), 7.8 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.8 – 7.7 (m, 1H), 7.5 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 7.4 (t, J = 7.5 Hz, 1H), 7.4 – 7.4 (m, 1H), 2.4 (s, 3H). ¹³C NMR (126 MHz, DMSO) δ 152.4, 148.7, 137.9, 134.5, 132.6, 131.94, 128.4, 128.2, 127.4, 126.5, 125.8, 124.8, 120.9, 40.0, 39.9, 39.7, 39.5, 39.4, 39.2, 39.0, 20.9.



2-(o-tolyl)quinazolin-4(3H)-one 3d¹ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and o-tolylmethanol (165 mg, 1.352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3d** (85%) as a white solid. ¹H NMR (600 MHz, CDCl₃) δ 9.8 (s, 1H), 8.3 (dt, J = 7.9, 1.2 Hz, 1H), 7.8 – 7.8 (m, 2H), 7.6 – 7.5 (m, 2H), 7.4 (td, J = 7.4, 1.4 Hz, 1H), 7.4 (dq, J = 7.7, 0.7 Hz, 2H), 2.5 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 162.7, 153.4, 149.2, 136.9, 135.0, 133.8, 131.7, 130.8, 128.7, 128.1, 127.2, 126.6, 126.5, 121.0, 77.4, 77.2, 76.9, 20.2.




2-(4-(tert-butyl)phenyl)quinazolin-4(3H)-one 3e⁵ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (4-(tert-butyl)phenyl)methanol (165 mg, 1.352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3e** (93%) as a white solid. ¹H NMR (600 MHz, CDCl₃) δ 11.59 (s, 1H), 8.34 (ddd, J = 7.9, 1.6, 0.6 Hz, 1H), 8.22 – 8.15 (m, 2H), 7.83 (ddd, J = 8.2, 1.3, 0.6 Hz, 1H), 7.79 (ddd, J = 8.3, 6.9, 1.5 Hz, 1H), 7.62 – 7.56 (m, 2H), 7.50 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 1.39 (s, 9H). ¹³C NMR (126 MHz, CDCl₃) δ 164.0, 155.4, 151.9, 149.8, 134.9, 130.1, 128.1, 127.3, 126.7, 126.5, 126.2, 121.0, 77.4, 77.2, 76.9, 35.2, 31.3.




2-(4-methoxyphenyl)quinazolin-4(3H)-one 3f¹ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (4-methoxyphenyl)methanol (138 mg, 1,352 mmol).

The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3f** (83%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.40 (s, 1H), 8.24 – 8.18 (m, 2H), 8.15 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.82 (ddd, *J* = 8.5, 7.1, 1.6 Hz, 1H), 7.74 – 7.69 (m, 1H), 7.49 (ddd, *J* = 8.1, 7.1, 1.2 Hz, 1H), 7.12 – 7.07 (m, 2H), 3.86 (s, 3H). ¹³C NMR (151 MHz, DMSO) δ 162.3, 161.9, 151.9, 148.9, 134.5, 129.4, 127.2, 126.1, 125.8, 124.8, 120.65, 114.0, 55.4, 40.1, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1.



2-(3,5-dimethoxyphenyl)quinazolin-4(3H)-one 3g⁴ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (3,5-dimethoxyphenyl)methanol (168 mg, 1,352 mmol).


The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3g** (76%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.47 (s, 1H), 8.17 – 8.13 (m, 1H), 7.85 – 7.79 (m, 1H), 7.76 – 7.71 (m, 1H), 7.51 (ddd, *J* = 8.0, 7.0, 1.0 Hz, 1H), 7.38 (d, *J* = 2.3 Hz, 2H), 6.68 (t, *J* = 2.3 Hz, 1H), 3.84 (s, 6H). ¹³C NMR (151 MHz, DMSO) δ 162.2, 160.5, 151.9, 148.5, 134.6, 134.5, 127.5, 126.6, 125.8, 121.1, 105.5, 103.8, 55.5, 40.1, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1.



2-(3-chlorophenyl)quinazolin-4(3H)-one 3h² prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (3-chlorophenyl)methanol (142 mg, 1,352 mmol). The product was


purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3h** (61%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.60 (s, 1H), 8.25 (d, *J* = 2.1 Hz, 1H), 8.17 (td, *J* = 5.4, 2.5 Hz, 2H), 7.88 – 7.83 (m, 1H), 7.77 (d, *J* = 8.1 Hz, 1H), 7.66 (dd, *J* = 7.9, 2.1 Hz, 1H), 7.57 (dt, *J* = 23.7, 7.7 Hz, 2H). ¹³C NMR

(151 MHz, DMSO) δ 162.1, 151.0, 148.4, 134.7, 134.6, 133.4, 131.1, 130.5, 127.5, 126.9, 126.4, 125.8, 121.1, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1.




2-(4-chlorophenyl)quinazolin-4(3H)-one 3i³ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (4-chlorophenyl)methanol (142 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate

(5:1)) to yield **3i** (68%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.59 (s, 1H), 8.31 – 8.19 (m, 2H), 8.16 (dd, J = 7.9, 1.5 Hz, 1H), 7.85 (tt, J = 8.2, 1.2 Hz, 1H), 7.75 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 8.2 Hz, 2H), 7.54 (td, J = 7.5, 1.2 Hz, 1H). ¹³C NMR (126 MHz, DMSO) δ 162.1, 151.3, 148.5, 136.2, 134.6, 131.5, 129.5, 128.6, 127.5, 126.7, 125.8, 121.0, 40.1, 40.0, 40.0, 39.8, 39.8, 39.7, 39.6, 39.5, 39.4, 39.3, 39.2, 39.0.



2-(3-fluorophenyl)quinazolin-4(3H)-one 3j⁵ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (3-fluorophenyl)methanol (126 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate


(5:1)) to yield **3j** (90%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.59 (s, 1H), 8.17 (dd, J = 7.9, 1.5 Hz, 1H), 8.07 (dt, J = 7.8, 1.2 Hz, 1H), 8.01 (dt, J = 10.5, 2.1 Hz, 1H), 7.86 (ddd, J = 8.4, 7.1, 1.6 Hz, 1H), 7.77 (dd, J = 8.3, 1.1 Hz, 1H), 7.61 (td, J = 8.0, 5.9 Hz, 1H), 7.58 – 7.51 (m, 1H), 7.45 (td, J = 8.7, 3.1 Hz, 1H). ¹³C NMR (126 MHz, DMSO) δ 162.0 (d, J = 243.8 Hz), 162.0, 151.0, 148.4, 135.0 (d, J = 7.8 Hz), 134.6, 130.7 (d, J = 8.4 Hz), 127.5, 126.8, 125.8, 123.9 (d, J = 2.8 Hz), 121.1, 118.2 (d, J = 21.1 Hz), 114.5 (d, J = 24.0 Hz).




2-(4-fluorophenyl)quinazolin-4(3H)-one 3k¹ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (4-fluorophenyl)methanol (126 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate

(5:1)) to yield **3k** (92%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.54 (s, 1H), 8.33 – 8.19 (m, 2H), 8.16 (dd, J = 7.9, 1.5 Hz, 1H), 7.84 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H), 7.74 (dd, J = 8.1, 1.2 Hz, 1H), 7.53 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 7.39 (td, J = 8.7, 1.7 Hz, 2H). ¹³C NMR (126 MHz, DMSO) δ 164.0 (d, J = 249.5 Hz), 162.2, 151.4,


134.6, 130.4 (d, $J = 9.0$ Hz), 129.2 (d, $J = 3.1$ Hz), 127.4, 126.6, 125.8, 120.8, 115.6 (d, $J = 21.9$ Hz).



2-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one **3l²** prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and (4-(trifluoromethyl)phenyl)methanol (176 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3l** (75%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.73 (s, 1H), 8.38 (d, $J = 8.1$ Hz, 2H), 8.19 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.93 (d, $J = 8.1$ Hz, 2H), 7.87 (ddd, $J = 8.7, 7.1, 1.6$ Hz, 1H), 7.78 (d, $J = 8.1$ Hz, 1H), 7.59 – 7.55 (m, 1H). ¹³C NMR (151 MHz, DMSO) δ 162.1, 151.1, 148.4, 136.6, 134.6, 131.1 (d, $J = 31.9$ Hz), 128.7, 127.6, 127.0, 125.8, 125.4 (q, $J = 3.8$ Hz), 124.8, 123.0, 121.2.




2-(naphthalen-1-yl)quinazolin-4(3H)-one **3m²** prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and naphthalen-1-ylmethanol (158 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3m** (80%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.65 (s, 1H), 8.25 – 8.20 (m, 1H), 8.20 – 8.15 (m, 1H), 8.12 (dt, $J = 8.3, 1.1$ Hz, 1H), 8.07 – 8.03 (m, 1H), 7.87 (ddd, $J = 8.1, 7.1, 1.6$ Hz, 1H), 7.80 (dd, $J = 7.1, 1.2$ Hz, 1H), 7.76 – 7.72 (m, 1H), 7.65 (dd, $J = 8.3, 7.1$ Hz, 1H), 7.62 – 7.56 (m, 3H). ¹³C NMR (151 MHz, DMSO) δ 161.8, 153.6, 148.7, 134.5, 133.1, 131.7, 130.3, 130.2, 128.3, 127.6, 127.4, 127.0, 126.7, 126.3, 125.8, 125.2, 125.0, 121.2.




2-(naphthalen-2-yl)quinazolin-4(3H)-one **3n⁴** prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and naphthalen-2-ylmethanol (158 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3n** (85%) as a white solid. ¹H NMR (600 MHz, DMSO) δ 12.66 (s, 1H),

8.83 (d, $J = 1.9$ Hz, 1H), 8.32 (dd, $J = 8.6, 1.9$ Hz, 1H), 8.20 (dd, $J = 7.9, 1.5$ Hz, 1H), 8.10 – 8.04 (m, 2H), 8.05 – 7.99 (m, 1H), 7.87 (ddd, $J = 8.4, 7.0, 1.6$ Hz, 1H), 7.81 (dd, $J = 8.1, 1.2$ Hz, 1H), 7.69 – 7.61 (m, 2H), 7.55 (ddd, $J = 8.1, 7.0, 1.2$ Hz, 1H). ^{13}C NMR (151 MHz, DMSO) δ 162.2, 152.2, 148.8, 134.6, 134.1, 132.3, 129.4, 128.9, 128.1, 128.1, 127.9, 127.6, 127.5, 126.9, 126.6, 125.9, 124.5, 121.0, 40.1, 39.9, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1.




2-(furan-2-yl)quinazolin-4(3H)-one 3o⁵ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and furan-2-ylmethanol (98 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3o** (84%)

as a white solid. ^1H NMR (600 MHz, CDCl_3) δ 10.87 (s, 1H), 8.36 – 8.29 (m, 1H), 7.81 – 7.75 (m, 2H), 7.67 (dd, $J = 1.7, 0.7$ Hz, 1H), 7.56 (dd, $J = 3.5, 0.8$ Hz, 1H), 7.48 (ddd, $J = 8.1, 5.4, 2.8$ Hz, 1H), 6.67 (dd, $J = 3.5, 1.7$ Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 162.6, 149.5, 146.5, 145.6, 143.6, 135.1, 127.9, 126.9, 126.7, 121.2, 114.1, 113.1, 77.4, 77.2, 76.9.




2-methylquinazolin-4(3H)-one 3p⁶ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and Ethanol (0.5 ml). The product was purified by column chromatography (silica gel, hexane/ethylacetate (2:1)) to yield **3p** (66%) as a white solid. ^1H NMR (600 MHz, CDCl_3) δ 12.1 (s, 1H),

8.3 (d, $J = 8.0$ Hz, 1H), 7.8 (t, $J = 7.6$ Hz, 1H), 7.7 (d, $J = 8.2$ Hz, 1H), 7.5 (t, $J = 7.6$ Hz, 1H), 2.6 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 164.4, 153.4, 149.5, 134.9, 127.0, 126.4, 126.2, 120.3, 22.0.




2-hexylquinazolin-4(3H)-one 3q⁶ prepared following general procedure A using compound **1a** (50 mg, 0.338 mmol) and hexan-1-ol (80 mg, 1,352 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (3:1)) to yield **3q**

(40%) as a white solid. ^1H NMR (600 MHz, CDCl_3) δ 12.5 (s, 1H), 8.3 (dd, J = 8.0, 1.6 Hz, 1H), 7.7 (ddd, J = 8.4, 6.9, 1.6 Hz, 1H), 7.7 (dd, J = 8.2, 1.3 Hz, 1H), 7.4 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 2.8 – 2.8 (m, 2H), 1.9 – 1.8 (m, 2H), 1.5 – 1.3 (m, 5H), 0.9 (t, J = 7.2 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 164.6, 157.3, 149.6, 134.6, 127.2, 126.2, 126.1, 120.5, 35.8, 31.4, 27.3, 22.3, 13.9.




7-methoxy-2-phenylquinazolin-4(3H)-one 3r² prepared following general procedure A using compound 4-methoxy-2-nitrobenzonitrile (50 mg, 0.281 mmol) and benzyl alcohol (121 mg, 1.124 mmol). The product was purified by column

chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3r** (89%) as a white solid. ^1H NMR (600 MHz, CDCl_3) δ 11.06 (s, 1H), 8.25 – 8.16 (m, 3H), 7.26 (s, 1H), 7.23 (d, J = 2.5 Hz, 1H), 7.08 (dd, J = 8.8, 2.5 Hz, 1H), 3.96 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 165.2, 163.1, 152.6, 151.9, 133.1, 131.8, 129.2, 128.1, 127.4, 117.2, 114.5, 108.7, 77.4, 77.2, 76.9, 55.9.




7-chloro-2-phenylquinazolin-4(3H)-one 3s¹ prepared following general procedure A using compound 4-chloro-2-nitrobenzonitrile (50 mg, 0.274 mmol) and benzyl alcohol (120 mg, 1.096 mmol). The product was purified by column chromatography (silica gel,

hexane/ethylacetate (5:1)) to yield **3s** (70%) as a white solid. ^1H NMR (600 MHz, DMSO) δ 12.67 – 12.64 (m, 1H), 8.24 – 8.17 (m, 2H), 8.15 (d, J = 8.5 Hz, 1H), 7.79 (dd, J = 2.1, 1.0 Hz, 1H), 7.65 – 7.59 (m, 1H), 7.59 – 7.51 (m, 3H). ^{13}C NMR (126 MHz, DMSO) δ 161.7, 153.8, 149.8, 139.1, 132.4, 131.7, 128.6, 127.9, 127.9, 126.7, 126.5, 119.8, 40.0, 39.95, 39.9, 39.8, 39.7, 39.6, 39.5, 39.4, 39.2, 39.0.




2,7-diphenylquinazolin-4(3H)-one 3t prepared following general procedure A using compound 3-nitro-[1,1'-biphenyl]-4-carbonitrile (50 mg, 0.223 mmol) and benzyl alcohol (96.336 mg, 0.892 mmol). The product was purified by column

chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3t** (90%) as a white solid. ^1H NMR (600 MHz, DMSO) δ 12.54 (s, 1H), 8.25 – 8.19 (m, 3H), 8.00 (d, J = 1.8 Hz, 1H), 7.84 (dt, J = 8.3, 2.6 Hz, 3H), 7.64 – 7.58 (m, 1H), 7.60 – 7.51 (m, 4H), 7.47 (dd, J = 8.4, 6.6 Hz, 1H). ^{13}C NMR (151 MHz, DMSO) δ 162.0, 152.8, 149.3, 146.2, 138.8, 132.7, 131.4, 129.2, 128.6, 128.6, 127.8, 127.2, 126.6, 125.3, 124.9, 119.9, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1.



7-(2-methoxyphenyl)-2-phenylquinazolin-4(3H)-one **3u**

prepared following general procedure A using compound 2'-methoxy-3-nitro-[1,1'-biphenyl]-4-carbonitrile (50 mg, 0.197 mmol) and benzyl alcohol (85 mg, 0.788 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3u** (72%) as a white solid. ^1H NMR (600 MHz, DMSO) δ 12.51 (s, 1H), 8.23 – 8.19 (m, 2H), 8.17 (d, J = 8.2 Hz, 1H), 7.82 (d, J = 1.6 Hz, 1H), 7.64 (dd, J = 8.2, 1.7 Hz, 1H), 7.62 – 7.53 (m, 3H), 7.43 (td, J = 7.3, 1.7 Hz, 2H), 7.21 – 7.16 (m, 1H), 7.10 (td, J = 7.4, 1.1 Hz, 1H), 3.82 (s, 3H). ^{13}C NMR (151 MHz, DMSO) δ 162.1, 156.2, 152.5, 148.6, 144.5, 132.8, 131.4, 130.5, 129.9, 128.6, 128.4, 127.9, 127.8, 127.7, 127.2, 125.5, 120.9, 119.5, 111.9, 55.6, 40.1, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1. HRMS (ESI) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{21}\text{H}_{16}\text{N}_2\text{O}_2$ 329.1245; found: 329.1283.



7-(4-(tert-butyl)phenyl)-2-phenylquinazolin-4(3H)-one **3v**

prepared following general procedure A using compound 4'-(tert-butyl)-3-nitro-[1,1'-biphenyl]-4-carbonitrile (50 mg, 0.179 mmol) and benzyl alcohol (77 mg, 0.716 mmol). The product was purified by column chromatography (silica gel, hexane/ethylacetate (5:1)) to yield **3v** (76%) as a white solid. ^1H NMR (600 MHz, DMSO) δ 12.52 (s, 1H), 8.25 – 8.18 (m, 3H), 7.97 (d, J = 1.8 Hz, 1H), 7.81 – 7.72 (m, 3H), 7.63 – 7.48 (m, 5H), 1.31 (s, 9H). ^{13}C NMR (151 MHz, DMSO) δ 161.7, 152.5, 150.9, 145.7, 135.7, 132.6, 130.9, 128.2, 127.5, 126.5, 126.2, 125.6, 124.7, 124.3, 119.5, 39.9, 39.8, 39.7, 39.5, 39.4, 39.2, 39.1, 34.0, 30.7. HRMS (ESI) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{24}\text{H}_{22}\text{N}_2\text{O}$ 355.1766; found: 355.1799.


References


1. T. Su, K. Sun, G. Lu and C. Cai, *ACS Sustain. Chem. Eng.*, 2022, **10**, 3872.
2. T. T. Nguyen, D. T. M. Chung, K. X. Nguyen, V. P. T. Nguyen, N. T. S. Phan and T. T. Nguyen, *ChemistrySelect*, 2024, **9**, e202303762.
3. L. Tang, X. Zhao, G. Zou, Y. Zhou and X. Yang, *Asian J. Org. Chem.*, 2016, **5**, 335.
4. Y. Hu, S. Li, H. Li, Y. Li, J. Li, C. Duanmu and B. Li, *Org. Chem. Front.*, 2019, **6**, 2744.
5. S. Mondal, S. Chakraborty, S. Khanra, S. Chakraborty, S. Pal, P. Brandao, and N. D. Paul, *J. Org. Chem.*, 2024, **89**, 5250.
6. Zhang, Z., et al., *Chem. Commun.*, 2015, **51**, 9205.

Copies of NMR spectra


2-phenylquinazolin-4(3H)-one 3a

22HUNG_6H146.10.fid
6H146-DMSO-1H





2-(m-tolyl)quinazolin-4(3H)-one 3c




22HUNG_6H94.1.2.fid
6H94.1-DMSO-C13CPD

Chemical structure: Cc1cccc(c1)/N=C2C(=O)c3ccccc3N2


Peak list (ppm):

- 162.16
- 152.36
- 148.73
- 137.86
- 134.50
- 132.62
- 131.94
- 128.44
- 128.24
- 126.45
- 125.80
- 124.84
- 120.94
- 40.05 DMSO
- 39.85 DMSO
- 39.85 DMSO
- 39.78 DMSO
- 39.69 DMSO
- 39.61 DMSO
- 39.52 DMSO
- 39.44 DMSO
- 39.35 DMSO
- 39.18 DMSO
- 39.12 DMSO
- 20.91

22HUNG_6H93.10.fid
6H93-CDCI3-1H




22HUNG_6H93.2.fid
6H93-CDCl3-C13CPD




2-(4-(tert-butyl)phenyl)quinazolin-4(3H)-one 3e



22HUNG_6H105.10.fid
6H105-CDCl3-1H





22HUNG_6H105.2.fid
6H105-CDCl3-C13CPD





2-(4-methoxyphenyl)quinazolin-4(3H)-one 3f





2-(3,5-dimethoxyphenyl)quinazolin-4(3H)-one 3g





2-(3-chlorophenyl)quinazolin-4(3H)-one 3h





2-(4-chlorophenyl)quinazolin-4(3H)-one 3i





2-(3-fluorophenyl)quinazolin-4(3H)-one 3j





2-(4-fluorophenyl)quinazolin-4(3H)-one 3k



2-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 3l




2-(naphthalen-1-yl)quinazolin-4(3H)-one 3m




2-(naphthalen-2-yl)quinazolin-4(3H)-one 3n

22HUNG_6H111.10.fid
6H111-DMSO-1H




22HUNG_6H111.2.fid
6H111-DMSO-C13CPD




2-(furan-2-yl)quinazolin-4(3H)-one 3o

22HUNG_6H130.10.fid
6H130-CDCl3-1H




22HUNG_6H130.2.fid
6H130-CDCl3-C13CPD




2-methylquinazolin-4(3H)-one 3p



22HUNG_6H437.10.fid
6H437-CDCl₃-1H



22HUNG_6H437.2.fid
6H437-CDCl₃-C13CPD




2-hexylquinazolin-4(3H)-one 3q




7-methoxy-2-phenylquinazolin-4(3H)-one 3r



22HUNG_6H126.10.fid
6H126-CDCl3-1H





22HUNG_6H126.2.fid
6H126-CDCl3-C13CPD




7-chloro-2-phenylquinazolin-4(3H)-one 3s







7-(2-methoxyphenyl)-2-phenylquinazolin-4(3*H*)-one 3u

22HUNG_6H135.10.fid
6H135-DMSO-1H




22HUNG_6H135.2.fid
6H135-DMSO-C13CPD





7-(4-(tert-butyl)phenyl)-2-phenylquinazolin-4(3H)-one 3v

22HUNG_6H132.10.fid
6H132-DMSO-1H



22HUNG_6H132.2.fid
6H132-DMSO-C13CPD

